Comprehensive Update on Allergic Rhinitis from an Otolaryngology Perspective: Clinical, Diagnostic, and Therapeutic Considerations

Abstract

Allergic rhinitis is a chronic inflammatory disorder of the nasal mucosa mediated by immunoglobulin E (IgE) following exposure to environmental allergens. It represents one of the most common conditions encountered in otolaryngology practice and constitutes a significant public health problem due to its high prevalence, chronic course, and negative impact on quality of life. Although not life threatening, allergic rhinitis is closely associated with asthma, chronic rhinosinusitis, otitis media, sleep disturbances, and impaired academic and work performance (1,3). Despite the availability of effective treatments, the disease remains underdiagnosed and frequently undertreated. This review aims to provide a comprehensive update on the epidemiology, pathophysiology, clinical manifestations, diagnostic approach, and current therapeutic strategies for allergic rhinitis from an otolaryngology perspective, emphasizing the importance of individualized and evidence-based management to optimize patient outcomes.

Keywords

Introduction

Allergic rhinitis is one of the most prevalent chronic diseases worldwide, affecting approximately 10–30% of the global population, with increasing incidence particularly in urbanized regions (4,5). It is characterized by nasal symptoms such as rhinorrhea, sneezing, nasal itching, and congestion, often accompanied by ocular manifestations. From an otolaryngological standpoint, allergic rhinitis is of particular importance due to its direct involvement of the upper airway and its strong association with other ear, nose, and throat disorders, including eustachian tube dysfunction, otitis media with effusion, turbinate hypertrophy, and chronic rhinosinusitis (6,7).

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative has played a central role in standardizing the classification, diagnosis, and management of allergic rhinitis, promoting an integrated airway concept that links upper and lower respiratory tract diseases (8). Nevertheless, gaps in diagnosis, poor adherence to therapy, and inadequate long-term control persist in routine clinical practice, highlighting the need for continuous medical education and updated clinical approaches (9).

DEVELOPMENT

Epidemiology and Risk Factors

The prevalence of allergic rhinitis varies significantly according to geographic location, climate, socioeconomic status, and environmental exposure (10). Genetic predisposition plays a major role, with higher incidence observed in individuals with a family history of atopy (11). Environmental factors such as air pollution, tobacco smoke exposure, indoor allergens, and early life allergen sensitization significantly contribute to disease development and progression (12,13).

In pediatric populations, allergic rhinitis frequently coexists with atopic dermatitis and asthma, forming part of the so called “atopic march,” which underscores the systemic nature of allergic disease (14).

Pathophysiology

Allergic rhinitis is a type I hypersensitivity reaction mediated by IgE. Initial sensitization occurs when allergens are processed by antigen presenting cells, leading to the production of allergen-specific IgE antibodies. Upon re-exposure, cross linking of IgE on mast cells and basophils triggers the release of inflammatory mediators such as histamine, leukotrienes, and prostaglandins (15).

The early phase reaction is responsible for acute symptoms including sneezing and rhinorrhea, while the late-phase reaction involves cellular infiltration by eosinophils, T lymphocytes, and cytokines, resulting in persistent nasal inflammation and congestion (16). Chronic inflammation may impair mucociliary clearance, promote turbinate hypertrophy, and predispose patients to secondary infections (17).

Clinical Manifestations and Classification

The hallmark symptoms of allergic rhinitis include nasal obstruction, watery rhinorrhea, sneezing, and nasal itching. Ocular symptoms such as conjunctival itching, tearing, and redness are also common (18). In children, chronic mouth breathing, snoring, and sleep disturbances may be prominent features.

According to ARIA guidelines, allergic rhinitis is classified as intermittent or persistent based on symptom duration, and as mild or moderate to severe depending on symptom intensity and impact on daily activities, sleep, and quality of life (8,19).

Diagnostic Approach

Diagnosis is primarily clinical and relies on a thorough medical history and physical examination. Anterior rhinoscopy and nasal endoscopy typically reveal pale, edematous nasal mucosa with clear secretions (20). Allergy testing, including skin prick testing and measurement of serum-specific IgE, is useful for identifying causative allergens and guiding environmental control and immunotherapy decisions (21).

Differential diagnosis includes non-allergic rhinitis, infectious rhinitis, and structural nasal abnormalities, which must be carefully excluded to ensure appropriate management (22).

Pharmacological Treatment

Pharmacologic therapy remains the cornerstone of allergic rhinitis management. Intranasal corticosteroids are considered first line treatment due to their potent anti-inflammatory effects and proven efficacy in controlling all nasal symptoms (23,24). Second generation antihistamines, administered orally or intranasally, are effective in mild to moderate disease and have a favorable safety profile with minimal sedation (25).

Additional therapeutic options include leukotriene receptor antagonists, intranasal anticholinergics, cromolyn sodium, and short-term use of topical decongestants, which should be used cautiously due to the risk of rhinitis medicamentosa (26).

Immunotherapy and Comprehensive Management

Allergen specific immunotherapy is the only disease modifying treatment for allergic rhinitis and has demonstrated long term benefits, including reduced symptom severity, decreased medication use, and prevention of asthma development (27,28). It is particularly indicated in patients with moderate to-severe disease who do not achieve adequate control with pharmacotherapy or who wish to reduce long-term medication dependence (29).

Patient education, allergen avoidance strategies, and regular follow up are essential components of comprehensive disease management and contribute significantly to treatment adherence and long-term success (30).

DISCUSSION

Allergic rhinitis should be understood as a complex, chronic inflammatory disease of the upper airway rather than a benign, isolated nasal condition. From an otolaryngology perspective, its clinical relevance lies not only in the burden of nasal symptoms but also in its close anatomical, functional, and immunological relationship with adjacent structures of the upper and lower respiratory tract (28,31). Increasing evidence supports the concept of “united airway disease,” in which allergic inflammation affects the nasal cavity, paranasal sinuses, middle ear, and bronchial tree as part of a single pathological continuum (31,32).

One of the most significant challenges in clinical practice is the underestimation of allergic rhinitis severity by both patients and healthcare providers. Many patients normalize chronic nasal symptoms and delay seeking medical attention, leading to persistent inflammation and the development of secondary complications such as turbinate hypertrophy, eustachian tube dysfunction, otitis media with effusion, and chronic rhinosinusitis (6,32). For otolaryngologists, early recognition and adequate treatment are essential to prevent structural and functional alterations that may require surgical intervention.

The diagnostic approach to allergic rhinitis remains predominantly clinical; however, diagnostic accuracy can be compromised by overlapping symptoms with non-allergic rhinitis, infectious rhinitis, or anatomical nasal obstruction (22). In this context, nasal endoscopy and allergy testing play a crucial complementary role, allowing for improved phenotyping and more targeted management strategies. Identifying specific allergen sensitization is particularly important when considering immunotherapy, which represents the only disease-modifying treatment currently available (27,29).

Pharmacological management has evolved significantly, with intranasal corticosteroids established as the cornerstone of therapy due to their superior efficacy in controlling nasal inflammation and congestion (23,24). Despite robust evidence supporting their safety and effectiveness, misconceptions regarding long-term adverse effects continue to limit patient adherence (33). This highlights the importance of patient education and clear communication regarding treatment goals, expected outcomes, and proper administration techniques. Otolaryngologists are uniquely positioned to reinforce these aspects during follow-up visits.

Another critical issue is treatment adherence, which remains suboptimal across all age groups (9,30). Poor adherence is often related to inadequate symptom perception, fear of side effects, cost, and inconvenience of daily medication use. Studies have demonstrated that structured education programs, shared decision-making, and simplified treatment regimens significantly improve adherence and symptom control (30). Incorporating these strategies into routine otolaryngology practice may lead to better long-term outcomes and reduced healthcare utilization.

Immunotherapy deserves special consideration in the discussion of allergic rhinitis management. Both subcutaneous and sublingual immunotherapy have demonstrated long-term efficacy in reducing symptoms, medication use, and disease progression, including the development of asthma (25,28). From an otolaryngological standpoint, immunotherapy should be considered not only as a last resort but as an early intervention in appropriately selected patients with moderate-to-severe disease, particularly those with clear allergen sensitization and persistent symptoms despite optimal pharmacological treatment.

Furthermore, allergic rhinitis has a well-documented impact on sleep quality and neurocognitive function, especially in pediatric populations (28). Chronic nasal obstruction contributes to sleep disordered breathing, daytime somnolence, impaired concentration, and behavioral disturbances. These effects underscore the broader systemic consequences of uncontrolled allergic rhinitis and reinforce the need for comprehensive evaluation beyond nasal symptoms alone.

Finally, emerging research on endotypes and biomarkers of allergic rhinitis may further refine diagnostic and therapeutic approaches in the future. Advances in precision medicine hold promise for more individualized treatment strategies based on inflammatory profiles and response predictors, potentially improving outcomes and reducing unnecessary treatments (31).

In summary, allergic rhinitis represents a multifaceted disease with significant otolaryngological implications. Effective management requires a holistic, evidence-based approach that integrates accurate diagnosis, optimized pharmacological therapy, consideration of immunotherapy, and continuous patient education. Addressing these elements comprehensively may substantially reduce disease burden, prevent complications, and improve overall quality of life.

CONCLUSION

Allergic rhinitis is a highly prevalent chronic inflammatory disease frequently encountered in otolaryngology practice. Its impact extends beyond nasal symptoms, affecting overall health, sleep quality, and daily functioning. Accurate diagnosis, classification based on severity, and a personalized, evidence-based therapeutic approach are essential for effective disease control. Ongoing education of both clinicians and patients is fundamental to reducing disease burden and improving quality of life.

REFERENCES

1. Bousquet, J., et al. (2001). Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology, 108(5), S147–S334.
2. Greiner, A. N., et al. (2011). Allergic rhinitis. Lancet, 378(9809), 2112–2122.
3. Blaiss, M. S. (2010). Quality of life in allergic rhinitis. Annals of Allergy, Asthma & Immunology, 105(5), 371–381.
4. Asher, M. I., et al. (2006). Worldwide trends in asthma symptoms. European Respiratory Journal, 28(2), 312–316.
5. Meltzer, E. O. (2016). Allergic rhinitis burden. Journal of Allergy and Clinical Immunology, 138(6), 1462–1468.
6. Skoner, D. P. (2001). Complications of allergic rhinitis. Journal of Allergy and Clinical Immunology, 108(1), S47–S52.
7. Fokkens, W. J., et al. (2012). EPOS 2012. Rhinology, 50(Suppl. 23), 1–298.
8. Bousquet, J., et al. (2008). ARIA update. Allergy, 63(Suppl. 86), 8–160. Canonica, G. W., et al. (2014). Adherence in allergic rhinitis. Clinical and Translational Allergy, 4(1), 1–9.
9. Pawankar, R. (2014). Allergic rhinitis and urbanization. World Allergy Organization Journal, 7(1), 1–10.
10.  Bloom, B., et al. (2013). Environmental factors. Pediatrics, 132(1), 101–110.
11. Kim, J. L., et al. (2017). Air pollution and rhinitis. Allergy, 72(5), 684–692.
12. Spergel, J. M. (2010). Atopic march. Annals of Allergy, Asthma & Immunology, 105(2), 99–106.
13. Galli, S. J., et al. (2008). Mast cells and IgE. Nature, 454(7203), 445–454.
14. Durham, S. R., et al. (2012). Pathophysiology. Journal of Allergy and Clinical Immunology, 130(5), 1046–1056.
15. Baroody, F. M. (2011). Nasal inflammation. Otolaryngologic Clinics of North America, 44(3), 549–564.
16. Wallace, D. V., et al. (2008). Diagnosis and management. Journal of Allergy and Clinical Immunology, 122(2), S1–S84.
17. Seidman, M. D., et al. (2015). Clinical practice guideline. Otolaryngology–Head and Neck Surgery, 152(S1), S1–S43.
18. Dykewicz, M. S., & Wallace, D. V. (2016). Practice parameter update. Annals of Allergy, Asthma & Immunology, 117(2), 120–145.
19. Bro?ek, J. L., et al. (2017). ARIA guidelines. Journal of Allergy and Clinical Immunology, 140(4), 950–958.
20. Scadding, G. K., et al. (2017). Optimal management. Clinical Otolaryngology, 42(5), 1137–1149.
21. Carr, W., et al. (2018). Intranasal corticosteroids. Allergy and Asthma Proceedings, 39(6), 414–421.
22. Wallace, D. V., et al. (2020). Treatment updates. Annals of Allergy, Asthma & Immunology, 125(4), 386–394.
23. Zanonica, G. W., et al. (2019). Antihistamines. World Allergy Organization Journal, 12(7), 100043.
24. Mösges, R., et al. (2011). Immunotherapy effectiveness. Allergy, 66(6), 724–732.
25. Durham, S. R., & Penagos, M. (2016). Sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 137(2), 339–349.
26. Roberts, G., et al. (2018). EAACI guidelines. Allergy, 73(4), 765–798.
27. Lin, S. Y., et al. (2013). Sleep and allergic rhinitis. Otolaryngology–Head and Neck Surgery, 148(1), 142–148.
28. Blaiss, M. S., et al. (2018). Patient education. Allergy and Asthma Proceedings, 39(2), 127–134.
29. Hellings, P. W., et al. (2020). United airway disease. Allergy, 75(2), 244–254.
30. Blaiss, M. S., Hammerby, E., Robinson, S., Kennedy-Martin, T., & Buchs, S. (2018). The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review. Annals of Allergy, Asthma & Immunology, 121(1), 43–52.  https://doi.org/10.1016/j.anai.2018.03.028
31. Hellings, P. W., Fokkens, W. J., Bachert, C., Akdis, C. A., Bieber, T., Agache, I., Bousquet, J. (2017). Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis.  Allergy, 72(9), 1297–1305.  https://doi.org/10.1111/all.13162
32. Lin, S. Y., Erekosima, N., Kim, J. M., Ramanathan, M., Suarez-Cuervo, C., Chelladurai, Y., Segal, J. B. (2013). Allergic rhinitis and chronic rhinosinusitis: Evidence-based systematic review. Otolaryngology–Head and Neck Surgery, 148(4), 563–581.https://doi.org/10.1177/0194599813479743